Lineage Cell Therapeutics, Inc. (TLV:LCTX)

Market Cap	932.53M +156.1%
Revenue (ttm)	46.66M +54.6%
Net Income	-202.72M
EPS	-0.90
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	27,484
Average Volume	6,945
Open	341.80
Previous Close	355.10
Day's Range	341.60 - 358.60
52-Week Range	163.60 - 666.00
Beta	1.60
RSI	23.62
Earnings Date	May 12, 2026

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1990
• Employees: 75
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: LCTX

Financial Performance

In 2025, Lineage Cell Therapeutics's revenue was $14.56 million, an increase of 53.24% compared to the previous year's $9.50 million. Losses were -$63.53 million, 241.4% more than in 2024.

Financial numbers in USD